Skip to main content

Table 1 Baseline Characteristics and Demographics

From: Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia

Baseline Characteristics Statistics
Total number of randomized patients, N 1694
Age, mean (SD) 63.1 (8.2)
Peak urine flow rate (Qmax)  
  Mild (Qmax > 15 ml/s), n (%) 11 (0.7%)
  Moderate (Qmax 10–15 ml/s), n (%) 837 (50.7%)
  Severe (Qmax < 10 ml/s), n (%) 802 (48.6%)
PSA (mg/L), mean (SD) 1.8 (1.6)
PVR (mL), mean (SD) 38.1 (42.0)
LUTS Severity  
  Moderate (IPSS 8–19), n (%) 1090 (64.4%)
  Severe (IPSS >= 20), n (%) 603 (35.6%)
Race/Ethinity  
  Asian, n (%) 763(45.0%)
  Caucasian, n (%) 861(50.8%)
  Hispanic Caucasian, n (%) 164 (9.7%)
  Non-Hispanic Caucasian, n (%) 697 (41.1%)
  Other Race, n (%) 70 (4.1%)
  1. SD: standard deviation; n: number of patients; PSA: Prostate-specific antigen; PVR: post-void residual urine volume; LUTS: Lower Urinary Tract Symptoms; Asian: from the 2 studies conducted in Asia; Caucasian/Other race: from the 2 studies conducted outside Asia. Values are from V1-V2, before enrolled into the single-blind placebo run in period.